591 results on '"Teoh, Hwee"'
Search Results
2. Abstract 4125300: Prognostic Value of NT-proBNP and the H2FPEF Score on Empagliflozin-associated Left Ventricular Remodeling: Insights from the EMPA-HEART and EMPA-HEART 2 CardioLink Trial
3. Vascular regenerative cell content in South Asians: the key learnings
4. Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial
5. Association of Cerebral Oximetry With Brain Ischemic Lesions and Functional Outcomes in Arch Repair
6. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
7. Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
8. Wearable Cardiac Rhythm Monitoring Device for Detection of Postoperative Atrial Fibrillation
9. Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trial
10. The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial
11. Risk Factors for Postrepair Elevated Mitral Gradient: A Post-hoc Analysis of a Randomized Trial
12. Abstract 16308: Comparison of Myocardial Mechanics Post Mitral Valve Repair With Leaflet Preservation vs. Leaflet Resection: A Sub-Analysis of the Randomized CAMRA CardioLink-2 Trial
13. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
14. A randomized trial comparing axillary versus innominate artery cannulation for aortic arch surgery
15. Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized Trial
16. SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis.
17. Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
18. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey
19. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
20. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
21. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
22. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
23. Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction
24. Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity
25. Disruption of endothelial cell intraflagellar transport protein 88 exacerbates doxorubicin-induced cardiotoxicity
26. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
27. Abstract 12880: Left Ventricular Mass Predicts Cardiac Reverse Remodeling in Patients With Type 2 Diabetes and Coronary Artery Disease Who Are Treated With Empagliflozin
28. Abstract 9865: Acute Infarcts on Brain MRI Following Aortic Arch Repair With Circulatory Arrest: Insights From the ACE Cardiolink-3 Randomized Trial
29. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
30. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
31. How I do it ─ superficial parasternal intercostal plane catheter insertion
32. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
33. Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk
34. GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.
35. Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes
36. A novel role of endothelial autophagy as a regulator of myocardial fatty acid oxidation
37. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
38. Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
39. Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
40. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey
41. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
42. Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People Not Living With Diabetes But With Cardiovascular Risk Factors
43. Association of Cerebral Oximetry with Brain Ischemic Lesions and Functional Outcomes in Arch Repair
44. Endothelial-specific deletion of autophagy-related 7 (ATG7) attenuates arterial thrombosis in mice
45. Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis: The CAMRA CardioLink-2 Study
46. A Patient-Level Pooled Analysis of 2 Empagliflozin Trials of Left Ventricular Remodeling
47. Adiponectin limits monocytic microparticle-induced endothelial activation by modulation of the AMPK, Akt and NFκB signaling pathways
48. Modulation of neurotransmitter amino acid release from the rat isolated spinal cord
49. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
50. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.